Cole E , Landsberg D , Russell D , et al..: A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transpl 2001; 72:845–850.
Birkeland SA : Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate maintenance therapy. Transpl 1998; 66:1207–1210.
Matas AJ , Kandaswamy R , Gillingham KJ , et al..: Prednisone-free maintenance immunosuppression: A 5-year experience. Am J Transpl 2005; 5:2473–2478.
Kaufman DB , Leventhal JR , Axelrod D , et al..: Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction—long-term results, Am J Transpl 2005; 5:2539–2548.
Opelz G , Dohler B , Laux G : Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transpl 2005; 5:720–728.
Luan FL , Steffick DE , Gadegbeku C , Norman SP , Wolfe R , Ojo AO : Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transpl, 2009; 9:160–168.
Woodle ES , First MR , Pirsch J , et al..: A prospective, randomized, double-blind, placebo controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term low-dose corticosteroid therapy. Ann Surg 2008; 248: 564–577.
Hricik DE , O’Toole MA , Schulak JA , Herson J : Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4:1300–1305.
Sinclair NR : Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147:645–657.
Adams PL : Long-term patient survival: strategies to improve overall health. Am J Kidney Dis 2006; 47 (4 Suppl 2): S65–S85.
Pascual J , Zamora J , Galeano C , et al..: Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009; 1: CD005632.
Rostaing L , Cantarovich D , Mourad G , et al..: Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transpl 2005; 79:807–814.
Shibatani M , Fujioka M , Arai Y , et al..: Degree of corticosteroid treatment within the first 2 months of renal transplantation has a strong influence on the incidence of osteonecrosis of the femoral head. Acta Orthop 2008; 79:631–636.
O’Shaughnessy EA , Dahl DC , Smith CL , Kasiske BL : Risk factors for fractures in kidney transplantation. Transpl 2002; 74:362–366.
Gaber LW , Gaber AO , Hathaway DK , Vera SR , Shokouh-Amiri MH : Routine early biopsy of allografts with delayed function: correlation of histopathology and transplant outcome. Clin Transpl 1996; 10:629–634.
Augustine JJ , Siu DS , Clemente MJ , et al..: Pre-transplant IFN-gamma ELISPOTs are associated with posttransplant renal function in African American renal transplant recipients. Am J Transplant 2005; 5:1971–1975.
Basadonna GP , Matas AJ , Gillingham KJ , et al..: Early versus late acute renal allograft rejection: impact on chronic rejection. Transpl 1993; 55:993–995.
Humar A , Gillingham K , Kandaswamy R , Payne W , Matas A : Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transpl 2007; 7:1948–1953.
Vítko S , Klinger M , Salmela K , et al..: Two corticosteroid-free regimens—tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil—in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transpl 2005; 80:1734–1741.